Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to rewire OCD fear circuits

NCT ID NCT06834217

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study at Yale investigates how people with OCD process fear and safety signals in the brain. Researchers will use mild electrical stimulation (tDCS) to see if it can improve fear extinction learning, which is key to exposure therapy. 180 adults with OCD will undergo brain scans and skin conductance tests while learning to distinguish threatening from safe cues. The goal is to understand the brain circuits involved and whether tDCS can normalize them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS)
What this could lead to
If successful, this could point toward a non-invasive brain stimulation technique to enhance exposure therapy for OCD.
What could go wrong
This is an early-stage mechanistic study, not a treatment trial. The results may not translate into a clinical therapy, and tDCS effects can be subtle or inconsistent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All Participant Inclusion Criteria would include: 1. 18 years of age or older 2. speak English fluently, and 3. able to provide written and verbal informed consent. * Obsessive-compulsive disorder (OCD) Inclusion Criteria would include: 1. meet criteria for OCD as determined by structured clinical interview 2. exhibit significant current symptoms of OCD 3. report duration of OCD symptoms of at least 1-year 4. OCD symptoms are primary or co-primary relative to other psychiatric diagnoses 5. stable psychiatric treatment (≥8-weeks) or no active treatment. 6. exhibit significant current symptoms of OCD as determined by the Dimensional Obsessive-Compulsive Scale (DOCS) (≥18). Exclusion Criteria: * All Participant Exclusion Criteria would include: 1. active severe substance use disorder(s) 2. acute suicidality 3. history of bipolar or psychotic disorder(s) 4. significant developmental disabilities 5. loss of consciousness \> 10 minutes 6. history of traumatic brain injury 7. major neurological disease 8. a positive pregnancy test 9. other brain stimulation or magnetic resonance imaging contraindications 10. new psychological treatment within the past 8 weeks 11. daily anxiolytic medication use (e.g., benzodiazepine). * Non-Clinical Control Exclusion Criteria would include: 1. meet current criteria for a psychiatric disorder as determined by structured clinical interview 2. active-psychotropic medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obsessive compulsive disorder (OCD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder obsessive-compulsive disorder psychiatric disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obsessive compulsive disorder (OCD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Temple Medical Center

    RECRUITING

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.